Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Robinson, 2005, Advances in malignant mesothelioma, N Engl J Med, 353, 1591, 10.1056/NEJMra050152 Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136 Bowen, 1995, Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand, J Exp Med, 181, 2213, 10.1084/jem.181.6.2213 Nelissen, 2000, Dynamic regulation of activated leukocyte cell adhesion molecule–mediated homotypic cell adhesion through the actin cytoskeleton, Mol Biol Cell, 11, 2057, 10.1091/mbc.11.6.2057 Whitney, 1995, The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site, J Biol Chem, 270, 18187, 10.1074/jbc.270.31.18187 Zimmerman, 2006, Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells, Blood, 107, 3212, 10.1182/blood-2005-09-3881 Swart, 2002, Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration, Eur J Cell Biol, 81, 313, 10.1078/0171-9335-00256 Ikeda, 2004, Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function, J Biol Chem, 279, 55315, 10.1074/jbc.M407776200 Lunter, 2005, Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity, Cancer Res, 65, 8801, 10.1158/0008-5472.CAN-05-0378 van Kempen, 2000, Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin, Am J Pathol, 156, 769, 10.1016/S0002-9440(10)64943-7 van Kilsdonk, 2008, Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule, Cancer Res, 68, 3671, 10.1158/0008-5472.CAN-07-5767 Ginestier, 2007, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell, 1, 555, 10.1016/j.stem.2007.08.014 Cheng, 2015, miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene SALL4, Oncol Rep, 34, 1923, 10.3892/or.2015.4168 Dalerba, 2007, Phenotypic characterization of human colorectal cancer stem cells, Proc Natl Acad Sci U S A, 104, 10158, 10.1073/pnas.0703478104 Ishiguro, 2012, Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma, J Thorac Oncol, 7, 890, 10.1097/JTO.0b013e31824af2db Thies, 2015, Expression of the stem cell factor nestin in malignant pleural mesothelioma is associated with poor prognosis, PLoS One, 10, e0139312, 10.1371/journal.pone.0139312 Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, 5, 1365, 10.1038/70932 Fanoni, 2011, New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas, Immunol Lett, 134, 157, 10.1016/j.imlet.2010.09.022 Terme, 2011, IL-18 induces PD-1–dependent immunosuppression in cancer, Cancer Res, 71, 5393, 10.1158/0008-5472.CAN-11-0993 Nishimura, 2001, PD-1: an inhibitory immunoreceptor involved in peripheral tolerance, Trends Immunol, 22, 265, 10.1016/S1471-4906(01)01888-9 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8 Fife, 2008, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x Cedres, 2015, Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM), PLoS One, 10, e0121071, 10.1371/journal.pone.0121071 Mansfield, 2014, B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis, J Thorac Oncol, 9, 1036, 10.1097/JTO.0000000000000177 Inaguma, 2016, Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors, Am J Surg Pathol, 40, 1133, 10.1097/PAS.0000000000000653 Inaguma, 2017, Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas, Mod Pathol, 30, 278, 10.1038/modpathol.2016.185 Miettinen, 2012, A simple method for generating multitissue blocks without special equipment, Appl Immunohistochem Mol Morphol, 20, 410, 10.1097/PAI.0b013e318245c82f Kanda, 2013, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 Miettinen, 2014, SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases, Am J Surg Pathol, 38, 410, 10.1097/PAS.0000000000000116 Ma, 2014, Cluster of differentiation 166 (CD166) regulated by phosphatidylinositide 3-kinase (PI3K)/AKT signaling to exert its anti-apoptotic role via yes-associated protein (YAP) in liver cancer, J Biol Chem, 289, 6921, 10.1074/jbc.M113.524819 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Kuang, 2009, Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1, J Exp Med, 206, 1327, 10.1084/jem.20082173 Curiel, 2003, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat Med, 9, 562, 10.1038/nm863 Bloch, 2013, Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages, Clin Cancer Res, 19, 3165, 10.1158/1078-0432.CCR-12-3314